*2.1. Materials*

Chitosan (CH) (β-(1-4)-linked *D*-glucosamine and *N*-acetyl-d-glucosamine) with a low molecular weight of 251 kDa, deacetylation degree 98%, (ChitoClear, Giusto Faravelli, Milan, Italy); chondroitin sodium sulfate (CS) (β-1,4-linked d-glucuronic acid and β-1,3-linked N-acetyl galactosamine) bovine 100 EP, with a low molecular weight of 14 kDa, mixture of chondroitin A (chondroitin 4 sulfate) and chondroitin C (chondroitin 6 sulfate) (Bioiberica, Barcellona, Spain); hyaluronic acid (HA) (based on β -1,3-linked N-acetylglucosamine and β-(1,4)-d-glucuronic acid) with a low molecular weight of 212 kDa (Bioiberica, Barcellona, Spain); and pullulan (PUL) (based on maltotriose repeating units, linear α 1-4 and α 1-6 glucan, produced by *Aureobasidium pullulans*) with a low molecular weight of ~200–300 kDa (food grade, Hayashibara, Japan, Giusto Faravelli, Milan, Italy) were used for the scaffold preparations. Citric acid (CA) (monohydrated citric acid, European Pharmacopeia grade, Carlo Erba, Milan, Italy) was used as a crosslinking agent. Norfloxacin (N) (Sigma-Aldrich, Milan, Italy) was used as an antimicrobial drug.
